journal article·2024-02-07

Riboflavin Crystals with Extremely High Water Solubility

Polina V. Krikunova, Eteri R. Tolordava, Natalya A. Arkharova, Denis N. Karimov, Tatiana V. Bukreeva, Valerii Z. Shirinian, Evgeny V. Khaydukov, Tatiana N. Pallaeva

Publisher page

Abstract

New insights into the unique biochemical properties of riboflavin (Rf), also known as vitamin B2, are leading to the development of its use not only as a vitamin supplement but also as a potential anti-inflammatory, immunomodulatory, antioxidant, anticancer, and antiviral agent, where it may play a role as an inhibitor of viral proteinases. At the same time, the comparison of the pharmacoactivity of Rf with its known metabolites, namely, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), is very complicated due to its poor water solubility: 0.1–0.3 g/L versus 67 g/L for FMN and 50 g/L for FAD, which is the limiting factor for its administration in clinical practice. In this study, we report the recrystallization procedure of the type A Rf crystals into the slightly hydrophobic type B/C and a new hydrophilic crystal form that has been termed the P type. Our method of Rf crystal modification based on recrystallization from dilute alkaline solution provides an unprecedented extremely high water solubility of Rf, reaching 23.5 g/L. A comprehensive study of the physicochemical properties of type P riboflavin showed increased photodynamic therapeutic activity compared to the known types A and B/C against clinical isolates of Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and Salmonella typhimurium . Importantly, our work not only demonstrates a simple and inexpensive method for the synthesis of riboflavin with high solubility, which should lead to increased bioactivity, but also opens up opportunities for improving both known and new therapeutic applications of vitamin B2.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Metabolomics and Mass Spectrometry Studies · Analytical Chemistry and Chromatography · Biochemical Analysis and Sensing Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

FSRC “Crystallography and Photonics” RAS, Moscow 119333, Russia

Gamaleya Research Institute of Epidemiology and Microbiology, Moscow 123098, Russia

N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow 119991, Russia

Funding

Russian Science Foundation · Ministry of Science and Higher Education of the Russian Federation · Alexander von Humboldt-Stiftung

References (58)

Show source-provided references
1. 10.1042/bst028028310.1042/bst0280283 ↗
2. 10.1159/00034311110.1159/000343111 ↗
3. 10.1007/s00239-004-2610-210.1007/s00239-004-2610-2 ↗
4. 10.1016/j.biomaterials.2015.11.05010.1016/j.biomaterials.2015.11.050 ↗
5. 10.1042/BJ2011032610.1042/BJ20110326 ↗
6. 10.1093/ajcn/77.6.135210.1093/ajcn/77.6.1352 ↗
7. 10.1016/j.fct.2013.07.01810.1016/j.fct.2013.07.018 ↗
8. 10.1080/10408398.2016.114510410.1080/10408398.2016.1145104 ↗
9. 10.3390/ijms2103095010.3390/ijms21030950 ↗
10. 10.1002/ana.2528610.1002/ana.25286 ↗
11. 10.1093/ecco-jcc/jjz20810.1093/ecco-jcc/jjz208 ↗
12. 10.3389/fphar.2022.75574510.3389/fphar.2022.755745 ↗
13. 10.1021/mp800046m10.1021/mp800046m ↗
14. 10.1021/acs.bioconjchem.6b0031710.1021/acs.bioconjchem.6b00317 ↗
15. 10.1021/acsami.3c0177110.1021/acsami.3c01771 ↗
16. 10.1186/s12934-020-01302-710.1186/s12934-020-01302-7 ↗
17. 10.1007/s10529-011-0833-z10.1007/s10529-011-0833-z ↗
18. 10.1134/S000368380902001X10.1134/S000368380902001X ↗
19. 10.1271/bbb.59.69410.1271/bbb.59.694 ↗
20. 10.1007/BF0017195210.1007/BF00171952 ↗
21. 10.1128/AEM.01541-1010.1128/AEM.01541-10 ↗
22. 10.1016/j.ymben.2009.01.00410.1016/j.ymben.2009.01.004 ↗
23. 10.1007/s10295-014-1422-710.1007/s10295-014-1422-7 ↗
24. 10.1146/annurev.bi.30.070161.00220510.1146/annurev.bi.30.070161.002205 ↗
25. 10.1248/bpb.b17-0029210.1248/bpb.b17-00292 ↗
26. 10.3945/an.116.01271610.3945/an.116.012716 ↗
27. 10.1016/j.apsb.2020.02.00810.1016/j.apsb.2020.02.008 ↗
28. Mohnicke M. · 2007
29. Sakate H. · Nagoya J. Med. Sci. · 1955 · 18 · 203
30. Dale, J. K. 2,603,633 Crystalline form of riboflavin. US patent office, 1952.
31. Dale, J. K. 2,797,215 Production of type A Riboflavin crystals. US patent office, 1957.
32. Gloor, A. US patent 7670800 Process for the purification of riboflavin. US patent office, 2010.
33. 10.1107/S205322962101217110.1107/S2053229621012171 ↗
34. 10.1016/0584-8539(86)80020-410.1016/0584-8539(86)80020-4 ↗
35. 10.1016/0924-2031(94)85004-610.1016/0924-2031(94)85004-6 ↗
36. 10.1021/jp804231c10.1021/jp804231c ↗
37. 10.1093/nar/gkn81010.1093/nar/gkn810 ↗
38. 10.1134/S1061933X2270008910.1134/S1061933X22700089 ↗
39. 10.1016/j.crmicr.2022.10011110.1016/j.crmicr.2022.100111 ↗
40. 10.1021/acs.chemrev.2c0078710.1021/acs.chemrev.2c00787 ↗
41. 10.1021/jf040116510.1021/jf0401165 ↗
42. 10.1562/0031-8655(2002)075<0585:PEOBAT>2.0.CO;210.1562/0031-8655(2002)075<0585:PEOBAT>2.0.CO;2 ↗
43. 10.1111/j.1751-1097.2011.00916.x10.1111/j.1751-1097.2011.00916.x ↗
44. 10.1016/j.jgar.2018.01.00510.1016/j.jgar.2018.01.005 ↗
45. 10.1111/aos.1340910.1111/aos.13409 ↗
46. 10.1111/vox.1241410.1111/vox.12414 ↗
47. 10.3390/molecules2101004210.3390/molecules21010042 ↗
48. 10.1038/nrd246810.1038/nrd2468 ↗
49. 10.1016/j.spjpm.2015.12.00610.1016/j.spjpm.2015.12.006 ↗
50. 10.1016/S0304-4157(00)00012-510.1016/S0304-4157(00)00012-5 ↗
51. 10.17116/molgen2021390412110.17116/molgen20213904121 ↗
52. McCrone W. C. · 1965 · 2 · 725
53. Bernstein J. · 2002
54. 10.1134/S107036321402042X10.1134/S107036321402042X ↗
55. 10.1248/cpb.32.417010.1248/cpb.32.4170 ↗
56. 10.3109/0363904850905746110.3109/03639048509057461 ↗
57. 10.1016/S1773-2247(04)50027-810.1016/S1773-2247(04)50027-8 ↗
58. 10.1016/0378-5173(84)90210-210.1016/0378-5173(84)90210-2 ↗